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Condensation 
Vaginal progesterone and cerclage are equally effective for preventing preterm 
birth in women with a singleton gestation, previous spontaneous preterm birth, and 
a sonographic short cervix 
Short title of the paper: Vaginal progesterone versus cerclage in women with a 
singleton gestation, previous spontaneous preterm birth and a short cervix  
Implications and Contributions  
A. To compare the efficacy of vaginal progesterone and cerclage in preventing 
preterm birth and adverse perinatal outcomes in women with a singleton gestation, 
previous spontaneous preterm birth and a midtrimester sonographic short cervix  
B. Both vaginal progesterone and cerclage were associated with a significant 
reduction in the risk of preterm birth <35 and <32 weeks of gestation and 
composite perinatal morbidity/mortality compared with placebo/no cerclage. 
Adjusted indirect comparison meta-analyses showed no statistically significant 
differences between vaginal progesterone and cerclage in preventing preterm birth 
<35 and <32 weeks of gestation, and composite perinatal morbidity/mortality  
C. This updated meta-analysis reaffirms that vaginal progesterone and cerclage 
are equally effective in preventing preterm birth and improving perinatal outcomes 
in women with a singleton gestation, previous spontaneous preterm birth, and a 
sonographic short cervix.  
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ABSTRACT 
BACKGROUND: An indirect comparison meta-analysis published in 2013 
reported that both vaginal progesterone and cerclage are equally efficacious for 
preventing preterm birth and adverse perinatal outcomes in women with a 
singleton gestation, previous spontaneous preterm birth and a sonographic short 
cervix. The efficacy of vaginal progesterone has been disputed after publication of 
the OPPTIMUM study.   
OBJECTIVE: To compare the efficacy of vaginal progesterone and cerclage in 
preventing preterm birth and adverse perinatal outcomes in women with a 
singleton gestation, previous spontaneous preterm birth and a midtrimester 
sonographic short cervix.    
DATA SOURCES: MEDLINE, EMBASE, LILACS, and CINAHL (from their 
inception to March 2018); Cochrane databases, bibliographies, and conference 
proceedings.  
STUDY ELIGIBILITY CRITERIA: Randomized controlled trials comparing vaginal 
progesterone with placebo/no treatment or cerclage with no cerclage in women 
with a singleton gestation, previous spontaneous preterm birth and a sonographic 
cervical length <25 mm. 
STUDY APPRAISAL AND SYNTHESIS METHODS: Updated systematic review 
and adjusted indirect comparison meta-analysis of vaginal progesterone versus 
cerclage using placebo/no cerclage as the common comparator. The primary 
outcomes were preterm birth <35 weeks of gestation and perinatal mortality. 
Pooled relative risks (RRs) with 95% confidence intervals (CIs) were calculated.  
RESULTS: Five trials comparing vaginal progesterone versus placebo (265 
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women) and 5 comparing cerclage versus no cerclage (504 women) were 
included. Vaginal progesterone, compared with placebo, significantly reduced the 
risk of preterm birth <35 and <32 weeks of gestation, composite perinatal 
morbidity/mortality, neonatal sepsis, composite neonatal morbidity, and admission 
to the neonatal intensive care unit (RRs from 0.29-0.68). Cerclage, compared with 
no cerclage, significantly decreased the risk of preterm birth <35, <37, <32, and 
<28 weeks of gestation, composite perinatal morbidity/mortality, and birthweigth 
<1500 g (RRs from 0.64-0.70). Adjusted indirect comparison meta-analyses did 
not show statistically significant differences between vaginal progesterone and 
cerclage in the reduction of preterm birth or adverse perinatal outcomes.  
CONCLUSIONS: Vaginal progesterone and cerclage are equally effective for 
preventing preterm birth and improving perinatal outcomes in women with a 
singleton gestation, previous spontaneous preterm birth, and a midtrimester 
sonographic short cervix. The choice of treatment will depend on adverse events 
and cost-effectiveness of interventions, and patient/physician’s preferences. 
Key words: prematurity; recurrent preterm birth; uterine cervix; cervical length; 
transvaginal ultrasound; perinatal mortality; admission to neonatal intensive care 
unit; birth weight <1500 g; progestin; progestogens; cervical stitch  
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INTRODUCTION     
Worldwide, an estimated 11.1% of all livebirths in 2010 were born preterm (14.9 
million babies).1 In the United States, the preterm birth rate had declined steadily 
from 2007 to 2014. In 2016, the rate of preterm birth rose to 9.85%, a 2% rise 
from 2015 and the second straight year of increase for this rate.2 Complications 
of preterm birth are the leading cause of neonatal mortality, responsible for 35% 
of the world's 2.6 million deaths that occurred in 2016.3 In addition to its 
contribution to neonatal and child morbidity and mortality, preterm birth has 
lifelong effects on neurodevelopmental functioning such as increased risk of 
cerebral palsy, intellectual disability, visual and hearing impairments, and  an 
increased risk of chronic disease in adulthood.4-11  
It is widely accepted that preterm birth is a syndrome caused by several 
pathological processes such as infection, vascular and decidual disorders, uterine 
overdistension, breakdown of maternal-fetal tolerance, a decline in progesterone 
action, and cervical disease.12-14 A previous spontaneous preterm birth is a well-
known risk factor for recurrent spontaneous preterm birth.15-27 A recent meta-
analysis reported that the overall risk of recurrent spontaneous preterm birth <37 
weeks of gestation was 30%.28 A short cervix, conventionally defined as a 
transvaginal sonographic cervical length ≤25mm in the midtrimester of 
pregnancy, is also an important risk factor for this condition and has emerged as 
one of the strongest and most consistent predictors of preterm birth in 
asymptomatic women with a singleton or twin gestation.29-67 The combination of 
previous spontaneous preterm birth and a short cervix markedly increases the 
risk of recurrent spontaneous preterm birth. Indeed, among women with a 
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previous spontaneous preterm birth, the risk of recurrent spontaneous preterm 
birth is about 3-fold higher in those with a cervical length ≤25 mm than in those 
with a cervical length >25 mm in the midtrimester.68,69  
Vaginal progesterone administration70-81 and the placement of a cervical 
cerclage71,75,82-88 have been proposed for preventing preterm birth in patients with 
a singleton gestation, previous spontaneous preterm birth, and a sonographic 
short cervix. In 2011, an individual patient data (IPD) meta-analysis evaluated the 
efficacy of cerclage for the prevention of preterm birth and perinatal morbidity and 
mortality in asymptomatic women with a singleton gestation, previous 
spontaneous preterm birth, and a cervical length <25 mm before 24 weeks of 
gestation.82 Cerclage, compared with no cerclage, significantly decreased the risk 
of preterm birth <37, <35, <32, and <28 weeks of gestation, composite perinatal 
morbidity and mortality, and birthweight <1500 g. In 2013, another IPD meta-
analysis reported that vaginal progesterone administration to women with the same 
characteristics was associated with a significant reduction in the risk of preterm 
birth <32 weeks of gestation, composite perinatal morbidity and mortality, 
composite neonatal morbidity, and admission to the neonatal intensive care unit 
(NICU).71 Data from these 2 IPD meta-analyses were used for performing an 
adjusted indirect comparison meta-analysis of vaginal progesterone versus 
cerclage using placebo/no cerclage as the common comparator.71 This indirect 
meta-analysis did not show statistically significant differences between vaginal 
progesterone and cerclage in the reduction of preterm birth or adverse perinatal 
outcomes in women with a singleton gestation, previous spontaneous preterm birth 
and a midtrimester cervical length <25 mm.71 It was concluded that both 
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interventions are equally efficacious for preventing preterm birth and adverse 
perinatal outcomes in these patients.    
To date, only two small randomized controlled trials have directly compared 
vaginal progesterone and cerclage in women with these characteristics.89,90 
However, the trials lacked power to detect group differences. In 2016, the 
OPPTIMUM study, which tested the effect of vaginal progesterone in women at risk 
for preterm birth, reported that vaginal progesterone did not reduce the risk of 
preterm birth or neonatal morbidity and mortality in the entire population, or in the 
subgroup of women with a cervical length ≤25 mm.91 Therefore, it is necessary to 
reassess the efficacy of vaginal progesterone in women with a singleton gestation, 
previous spontaneous preterm birth and a midtrimester sonographic short cervix, 
and to update the adjusted indirect comparison meta-analysis of vaginal 
progesterone versus cerclage in patients with these characteristics. Adjusted 
indirect comparisons offer a unique opportunity to compare competing 
interventions. Their results usually, but not always, agree with the results of head-
to-head randomized controlled trials.92-98 When direct evidence from randomized 
controlled trials is lacking or insufficient, the adjusted indirect comparison meta-
analysis may provide useful information on the relative efficacy of the competing 
interventions.  
The aim of this study was to compare the efficacy of vaginal progesterone 
and cerclage in preventing preterm birth and adverse perinatal outcomes in women 
with a singleton gestation, previous spontaneous preterm birth and a midtrimester 
sonographic short cervix by using adjusted indirect comparison meta-analytic 
techniques. 
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MATERIALS AND METHODS                                                                                                                                              
This updated indirect comparison meta-analysis was performed according to the 
Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) 
guidelines99 and suggested guidelines for IPD100 and indirect meta-analyses.101 To 
ensure consistency, we used the same methodology as in our previous study.71 
The study protocol was prospectively registered with the PROSPERO database of 
systematic reviews (CRD42017077311). Two of the authors (AC-A and RR) 
independently retrieved and reviewed studies for eligibility, assessed their risk of 
bias, and extracted data. All disagreements encountered in the review process 
were resolved through consensus.  
Literature search and study selection    
In our previous indirect comparison meta-analysis,71 MEDLINE, EMBASE, 
CINAHL, LILACS, the Cochrane Central Register of Controlled Trials, and 
Research Registers of ongoing trials were searched from the inception of each 
database to October 31, 2012. An updated literature search was undertaken in 
these databases from November 1, 2012 to March 20, 2018 using a combination of 
keywords and text words related to progesterone, cervical cerclage, and preterm 
birth to identify randomized controlled trials comparing vaginal progesterone versus 
placebo/no treatment, or cerclage versus no cerclage for the prevention of preterm 
birth in women with singleton gestations. Google Scholar, proceedings of 
congresses/meetings on maternal-fetal medicine, reference lists of identified 
studies, and review articles were also searched. There were no language 
restrictions. Trials were eligible if the primary aim of the study was to prevent 
preterm birth in asymptomatic women with a singleton gestation, previous 
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 10
spontaneous preterm birth and a sonographic short cervix (cervical length <25 mm) 
in the midtrimester, or to prevent preterm birth in women with other characteristics 
but for whom outcomes were available in those with a singleton gestation, previous 
spontaneous preterm birth, and a pre-randomization cervical length <25 mm. Trials 
were excluded if they (1) were quasi-randomized, (2) assessed vaginal 
progesterone in women with threatened or arrested preterm labor, second 
trimester bleeding or premature rupture of membranes, (3) evaluated vaginal 
progesterone administration in the first trimester to prevent miscarriage, (4) 
assessed history-indicated cerclage (placed for the sole indication of poor obstetric 
history),  physical examination-indicated cerclage (placed for second-trimester 
cervical dilatation), or  compared different cerclage techniques or outpatient 
cerclage versus inpatient cerclage, or (5)  did not provide data for women with a 
singleton gestation, previous spontaneous preterm birth, and cervical length <25 
mm in the midtrimester.   
Data collection and extraction 
For the IPD meta-analysis that compared vaginal progesterone versus placebo, we 
contacted the principal investigators of eligible trials to request access to the data. 
Authors were supplied with a data extraction sheet and requested to supply 
anonymized data about baseline characteristics, interventions and outcomes for 
each randomized patient in the trial. Data provided by the investigators were 
systematically checked for completeness, duplication, consistency, feasibility, and 
integrity of randomization. Inconsistencies or missing data were discussed with the 
authors and corrections were made when deemed necessary. Finally, data on 
participant characteristics and outcomes were extracted for women with a singleton 
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 11
gestation, previous spontaneous preterm birth and a cervical length <25 mm, and 
were uploaded to the main study database. We also extracted data from each 
study on its characteristics and details of interventions. For studies comparing 
cerclage versus no cerclage, data on proportions and relative risks (RRs) with 95% 
confidence intervals (CIs) for each outcome measure were extracted from the IPD 
meta-analysis by Berghella et al,82 which used a similar approach to that described 
above.  
Outcome measures  
The prespecified primary outcomes were preterm birth <35 weeks of gestation and 
perinatal mortality. Secondary outcomes were preterm birth <37, <32, and <28 
weeks of gestation, respiratory distress syndrome, grade III/IV intraventricular 
hemorrhage, necrotizing enterocolitis, neonatal sepsis, bronchopulmonary 
dysplasia, composite neonatal morbidity (defined as the occurrence of any of the 
above mentioned neonatal morbidities), composite perinatal morbidity and mortality 
(defined as the occurrence of any of the above mentioned neonatal morbidities or 
perinatal death), admission to the neonatal intensive care unit (NICU), and 
birthweight <2500 g and <1500 g.  
Risk of bias Assessment 
Assessments of risk of bias for included trials were done according to the seven 
domains outlined in the Cochrane Handbook for Systematic Reviews of 
Interventions (random sequence generation, allocation concealment, blinding of 
participants and personnel, blinding of outcome assessment, incomplete outcome 
data, selective reporting, and other bias).102 This tool categorizes studies by low, 
unclear, or high risk of bias in each domain. 
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Statistical analysis  
For studies comparing vaginal progesterone versus placebo, we performed an IPD 
meta-analysis using a two-stage approach. In the first stage, estimates of effect 
were derived from the IPD for each trial, and in the second stage, these were 
combined using standard methods for meta-analyses of aggregate data to give a 
pooled RR with 95% CI.103 A similar approach was used in the IPD meta-analysis 
of trials that evaluated cerclage versus no cerclage.82 Heterogeneity of the results 
among studies was tested with the quantity І2 in the IPD meta-analysis of vaginal 
progesterone versus placebo104 and the Mantel-Haenszel Q statistics in the IPD 
meta-analysis of cerclage versus no cerclage. Results from individual studies were 
pooled using a fixed-effects model if substantial statistical heterogeneity was not 
present (І2 ≤30% or P ≥0.10 for Mantel-Haenszel Q statistics). Otherwise, random-
effects models were used to pool data across studies.  
Number needed to treat (NNT) with 95% CI was calculated where meta-
analysis of dichotomous outcomes revealed a statistically significant beneficial or 
harmful effect of vaginal progesterone or cerclage.105 We also planned to explore 
potential sources of heterogeneity and to assess publication and related biases if 
at least ten studies were included in a meta-analysis but these analyses were not 
undertaken due to the limited number of trials included in the review. 
The adjusted indirect comparison meta-analysis of vaginal progesterone 
versus cerclage was performed according to the Bucher’s method.106 In this 
approach, the direct comparisons A versus B and C versus B with the common 
comparator link B are used to yield an indirect comparison of A versus C. As 
vaginal progesterone and cerclage have been compared to placebo and no 
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 13
cerclage, respectively, indirect comparison was enabled by the “common” 
placebo/no cerclage arms. An extension of the Bucher’s method was used to 
convert the summary estimates (lnRRs) and measures of uncertainty (variances) 
from the two meta-analyses into a RR (95% CI) that represented the difference 
between vaginal progesterone and cerclage. This method is well validated and 
recommended as the preferred method for indirect comparison, superior to other 
methods, as it preserves the randomization and retains the methodological 
properties of the randomized controlled trials.92,94,96,107 
We carried out a subgroup analysis (direct and adjusted indirect 
comparisons) for women with a cervical length <16 mm. Moreover, we performed a 
sensitivity analysis (direct and adjusted indirect comparisons) to explore the impact 
of co-interventions on the direction and size of effect for preterm birth and perinatal 
mortality. In this sensitivity analysis, we excluded women who received 17α-
hydroxyprogesterone caproate (17-OHPC) or vaginal progesterone in trials that 
compared cerclage versus no cerclage and women who received a cerclage in 
studies that compared vaginal progesterone with placebo. This analysis was 
performed because it is unclear whether the effects of progesterone and cerclage 
are additive in women with a singleton gestation, previous spontaneous preterm 
birth, and a short cervix. A prespecified sensitivity analysis to explore the impact of 
study quality on results was not carried out because all trials were considered as at 
low risk of bias. Subgroup and sensitivity analyses were performed only for the 
outcomes measures preterm birth <35 and <32 weeks of gestation, and perinatal 
mortality. 
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One author (AC-A) conducted all statistical analyses using Review Manager 
software (version 5.3.5; Nordic Cochrane Centre, Copenhagen, Denmark) for 
performing direct meta-analyses and Indirect Treatment Comparison software 
(version 1.0; Canadian Agency for Drugs and Technologies in Health, Ottawa, 
Canada) to perform adjusted indirect comparison meta-analyses. 
This study was exempted from review by the Human Investigation 
Committee Administration Office of Wayne State University because all included 
studies were published previously and had each received local Institutional Review 
Board approvals and informed consent from participants. 
RESULTS 
Results of the search  
Our previous search yielded 32 potentially relevant studies of which 9 were 
included (4 comparing vaginal progesterone versus placebo108-111 and 5 comparing 
cerclage versus no cerclage112-116). The updated search identified 4 randomized 
controlled trials that compared vaginal progesterone versus placebo91,117-119 and 
1120 that compared cerclage versus no cerclage in singleton gestations with the 
aim of preventing preterm birth and/or adverse perinatal outcomes. Three of the 
four studies that assessed vaginal progesterone versus placebo were excluded 
because they included women without previous spontaneous preterm birth,117 or 
women with a short cervix (cervical length ≤28 mm) who underwent cerclage 
before randomization,118 and data on cervical length were not collected before 
randomization.119 A trial that assessed cerclage versus no cerclage in singleton 
gestations with a short cervix (cervical length <25 mm) was excluded because data 
on 14 women with a previous preterm birth that were included in this study could 
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not be obtained.120 Thus, only a new trial (the OPPTIMUM study91) was included in 
this updated indirect comparison meta-analysis. In total, 10 trials met the inclusion 
criteria which provided data for 769 women with a singleton gestation, previous 
spontaneous preterm birth, and a cervical length <25 mm at midtrimester.  
Characteristics and risk of bias of included studies 
Table 1 depicts the main characteristics of the 10 studies included in this indirect 
comparison meta-analysis. Five double-blind, placebo-controlled trials, including 
265 women, compared vaginal progesterone versus placebo.91,108-111 Two studies 
evaluated the use of vaginal progesterone in women with a short cervix (cervical 
length ≤15 mm108 and cervical length between 10 and 20 mm111), one in women 
with a previous spontaneous preterm birth,109 one in women with a previous 
spontaneous preterm birth, uterine malformations or twin gestation,110 and the 
remainder in women with a previous spontaneous preterm birth, short cervix 
(cervical length ≤25 mm), or a positive fetal fibronectin test combined with other 
clinical risk factors for preterm birth.91 The daily dose of vaginal progesterone used 
in the trials varied from 90-200 mg and the treatment was administered from 18-25 
to 34-36 weeks of gestation. Thirty women (25 in the study by Norman et al91 and 5 
in the study by Hassan et al111) underwent a cerclage after randomization.   
Five trials, including 504 women, compared cerclage versus no cerclage in 
women with a sonographic short cervix.112-116 Gestational age at cervical length 
screening varied between 14 and 24 weeks of gestation. Four trials used the 
McDonald procedure112,113,115,116 and one used the Shirodkar technique.114 Rescue 
cerclage in women allocated to the no cerclage group was allowed in three studies 
based on physical examination116 or on ultrasonographic cervical changes.112,113 In 
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the trial by Owen et al,116 99 women received 17-OHPC and one received vaginal 
progesterone.121    
All 10 studies that were included in the meta-analysis had adequate random 
sequence generation and allocation concealment, were free of selective outcome 
reporting, and had adequate handling of incomplete outcome data. In the 5 trials 
that evaluated vaginal progesterone, there was blinding of participants, health care 
providers and outcome assessors. In the 5 trials that evaluated cerclage, blinding 
of participants and personnel was not feasible due to the nature of the intervention. 
It was unclear if outcome assessors were blinded from knowledge of which 
intervention a participant received. However, we considered that assessment of 
most outcomes included in our review are objective in nature and thus, were not 
likely to be influenced by a lack of blinding in studies that evaluated cerclage. All 
but one study91 had no obvious risk of other biases. In fact, the study by Norman et 
al91 was at high risk of compliance bias because only 66% of patients with a 
cervical length ≤25 mm had a compliance ≥80%, which can affect the trial’s 
statistical power to detect the effects of intervention.122 Overall, all 10 trials were 
considered to be at low risk of bias.   
Comparability of the vaginal progesterone and cerclage trials 
All women included in this updated indirect comparison meta-analysis (265 from 
trials that evaluated vaginal progesterone and 504 from trials that evaluated 
cerclage) had a singleton gestation, previous spontaneous preterm birth, and a 
cervical length <25 mm detected in the midtrimester (most at 16-24 weeks of 
gestation). The percentage of patients with a cervical length <16 mm was 42.6% in 
the trials that evaluated vaginal progesterone and 30.6% in the trials that evaluated 
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cerclage. Women included in the trials that evaluated vaginal progesterone had a 
mean (SD) age and body mass index of 27.0 (6.3) years and 29.4 (6.5) kg/m2, 
respectively, and Black and White women represented 75% of the study 
population. The sociodemographic characteristics of women included in the IPD 
meta-analysis that evaluated cerclage were not reported in the study publication.82 
However, patient characteristics reported in individual trials of cerclage were 
comparable to those of patients who participated in trials of vaginal progesterone. 
For example, in the study by Owen et al,116 the largest that assessed cerclage, 
Black and White women represented 75% of the study population and the mean 
age and body mass index were 26.5 years and 29.6 kg/m2, respectively. Finally, 
the rates of most outcome measures in the control groups of trials that evaluated 
vaginal progesterone and cerclage were similar (Table 2).  
Direct comparisons  
Vaginal progesterone administration to patients with a singleton gestation, previous 
spontaneous preterm birth, and a midtrimester cervical length <25 mm significantly 
reduced the risk of preterm birth <35 weeks (RR 0.68; 95% CI, 0.50-0.93) and <32 
weeks of gestation (RR, 0.60; 95% CI, 0.39-0.92), neonatal sepsis (RR, 0.38; 95% 
CI, 0.15-0.96), composite neonatal morbidity (RR, 0.29; 95% CI, 0.11-0.81), 
composite perinatal morbidity and mortality (RR, 0.43; 95% CI, 0.20-0.94), and 
admission to the NICU (RR, 0.46; 95% CI, 0.30-0.70) (Table 2).  
The use of cerclage in women with a singleton gestation, previous 
spontaneous preterm birth, and a cervical length <25 mm in the midtrimester was 
associated with a significantly lower risk of preterm birth <35 weeks (RR 0.70; 95% 
CI, 0.55-0.89), <37 weeks (RR 0.70; 95% CI, 0.58-0.83), <32 weeks (RR, 0.66; 
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95% CI, 0.48-0.91), and <28 weeks of gestation (RR 0.64; 95% CI, 0.43-0.96), 
composite perinatal morbidity and mortality (RR, 0.64; 95% CI, 0.45-0.91), and 
birthweight <1500 g (RR, 0.64; 95% CI, 0.45-0.90). NNTs for vaginal progesterone 
varied from 5-16 (median, 7) and for cerclage from 6-14 (median, 11). 
Both, vaginal progesterone and cerclage were associated with a non-
significant decrease in the risk of perinatal mortality (RR, 0.63; 95% CI, 0.26-1.56 
for vaginal progesterone and RR, 0.65; 95% CI, 0.40-1.07 for cerclage) and 
respiratory distress syndrome (RR, 0.38; 95% CI, 0.13-1.07 for vaginal 
progesterone and RR, 0.61, 95% CI, 0.32-1.19 for cerclage). The rates of grade 
III/IV intraventricular hemorrhage, necrotizing enterocolitis, bronchopulmonary 
dysplasia, and birthweight <2500 g did not differ significantly between the vaginal 
progesterone and placebo groups, and between the cerclage and no cerclage 
groups. There was no substantial heterogeneity in any of the meta-analyses that 
compared vaginal progesterone versus placebo and cerclage versus no cerclage.   
Indirect comparison 
Adjusted indirect comparison meta-analyses showed no statistically significant 
differences between vaginal progesterone and cerclage in preventing preterm birth 
<35 weeks of gestation (RR, 0.97; 95% CI, 0.66-1.44; P=0.93) and perinatal death 
(RR, 0.97; 95% CI, 0.35-2.69; P=0.96) (Table 3). There were no significant 
differences between vaginal progesterone and cerclage for any of the secondary 
outcome measures. Estimated RRs ranged from 0.48 for composite neonatal 
morbidity (favoring vaginal progesterone) to 1.79 for grade III/IV intraventricular 
hemorrhage (favoring cerclage), but all 95% CIs included 1 with most P values 
>0.75. These results indicate that vaginal progesterone and cerclage are not 
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significantly different in terms of efficacy for reducing the risk of preterm birth and 
adverse perinatal outcomes.  
Subgroup and sensitivity analyses 
Among women with a cervical length <16 mm, both vaginal progesterone and 
cerclage were associated with a significant reduction in the risk of preterm birth 
<35 weeks of gestation (Table 4). Moreover, cerclage significantly reduced the rate 
of preterm birth <32 weeks of gestation these patients. Vaginal progesterone and 
cerclage significantly decreased the risk of preterm birth <35 and <32 weeks of 
gestation in a sensitivity analysis that excluded both patients who received 
progestogens in trials that evaluated cerclage and those in whom a cerclage was 
placed in trials that evaluated vaginal progesterone. No statistically significant 
differences were observed in the adjusted indirect comparisons between vaginal 
progesterone and cerclage in subgroup and sensitivity analyses.  
COMMENT 
Principal findings of the study  
The results of this updated indirect comparison meta-analysis indicate that vaginal 
progesterone and cerclage are equally efficacious in preventing preterm birth in 
women with a singleton gestation, previous spontaneous preterm birth, and a 
sonographic short cervix. Indeed, vaginal progesterone significantly decreased the 
risk of preterm birth <35 and <32 weeks of gestation, neonatal sepsis, composite 
neonatal morbidity, composite perinatal morbidity and mortality, and admission to 
NICU as compared with placebo. On the other hand, cerclage was associated with 
a significant reduction in the risk of preterm birth <37, <35, <32, and <28 weeks of 
gestation, composite perinatal morbidity and mortality, and birthweight <1500 g 
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when compared with no cerclage. Both interventions were associated with a non-
significant ~36% reduction in the rate of perinatal death. Adjusted indirect 
comparisons showed that there were no significant differences between the 
efficacy of vaginal progesterone and cerclage in the prevention of preterm birth or 
adverse perinatal outcomes. These findings were consistent with sensitivity 
analyses that excluded patients who received co-interventions. Finally, a subgroup 
analysis revealed that both interventions significantly reduced the rate of preterm 
birth <35 weeks of gestation in women with a cervical length <16 mm.  
Thus far, only two small randomized controlled trials have directly compared 
vaginal progesterone and cerclage in women with a singleton gestation, previous 
spontaneous preterm birth, and a short cervix.89,90 Ionescu et al89 performed a 
randomized controlled trial, reported in abstract form only, in which women with a 
singleton gestation, previous preterm birth, and a cervical length <25 mm before 24 
weeks of gestation were randomly assigned to receive either vaginal progesterone 
200 mg/d (N=46) or cerclage (N=46). The mean gestational age at delivery was not 
significantly different between women allocated to receive vaginal progesterone 
(31.5 weeks) and those allocated to receive a cerclage (32.9 weeks). 
Chandiramani et al90 conducted a randomized controlled trial that compared 
vaginal progesterone 400 mg/d (N=17) versus cerclage (N=19) in women with a 
singleton gestation, at least one previous spontaneous preterm birth, and a cervical 
length <25 mm before 24 weeks of gestation. There was no statistically significant 
difference in mean gestational at delivery between the vaginal progesterone (31.5 
± 9.0 weeks) and cerclage (33.7 ± 7.7 weeks) groups (P=0.23). The authors of 
these trials provided additional information to a Cochrane review that assessed the 
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use of cerclage in women with singleton gestations at high risk for preterm birth,123 
which allowed the performance of direct comparison meta-analyses between 
vaginal progesterone and cerclage in women with a singleton gestation, previous 
spontaneous preterm birth, and a cervical length <25 mm in the midtrimester. In 
accordance with the results of our indirect comparison meta-analysis, the 
Cochrane review reported that there were no significant differences between 
cerclage and vaginal progesterone in the risk of preterm birth <37 weeks (RR, 
1.16; 95% CI, 0.64-2.08), <34 weeks (RR, 1.01; 95% CI, 0.51-2.01), and <28 
weeks of gestation (RR, 0.92; 95% CI, 0.37-2.27), perinatal mortality (RR, 0.94; 
95% CI, 0.36-2.48), and serious neonatal morbidity (RR, 0.49; 95% CI, 0.05-
4.52).123 However, data from one study89 showed that the rates of both preterm 
premature rupture of membranes and use of tocolytic agents were significantly 
higher in the cerclage group than in the vaginal progesterone group (17% versus 
2%; RR, 8.00; 95% CI, 1.04-61.42 for preterm premature rupture of membranes; 
and 65% versus 17%; RR, 3.75; 95% CI, 1.93-7.29 for use of tocolytic agents). In 
the absence of adequately powered, high-quality, randomized controlled trials 
comparing vaginal progesterone and cerclage, our indirect comparison treatment 
meta-analysis provides the best available evidence regarding comparative efficacy 
of the two interventions. 
Strengths and limitations  
The main strengths of our study include: (1) the rigorous methodology used for 
performing the indirect comparison meta-analysis; (2) the use of individual patient 
data from direct comparisons of vaginal progesterone versus placebo and cerclage 
versus no cerclage for performing indirect comparisons of vaginal progesterone 
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versus cerclage; (3) the low risk of bias for most trials included in the review; (4) 
the comparability of trial and patients characteristics between studies that 
evaluated vaginal progesterone and those that evaluated cerclage; (4) the 
remarkably similar rates of preterm birth and adverse perinatal outcomes found in 
control groups of trials that evaluated vaginal progesterone and cerclage making 
more homogeneous the common comparator placebo/no cerclage in indirect meta-
analyses; (5) the absence of statistical heterogeneity in all direct meta-analyses 
performed; (6) the robustness of the study findings to sensitivity analyses restricted 
to patients who did not receive co-interventions; and (7) the consistency between 
the results obtained in our indirect comparison meta-analysis and those obtained in 
the meta-analysis123 of two trials that directly compared vaginal progesterone and 
cerclage.   
Some potential limitations must also be considered. First, the OPPTIMUM 
study91 did not collect data on respiratory distress syndrome, the most common 
complication of preterm birth, which reduced the sample size of meta-analyses for 
the composite outcomes of neonatal morbidity and perinatal morbidity and mortality 
in the comparison vaginal progesterone versus placebo. Second, data for 14 
patients with a singleton gestation, previous preterm birth, and cervical length <25 
mm who participated in a trial120 that compared Shirodkar cerclage, McDonald 
cerclage, and bed rest (no cerclage) could not be obtained from the investigators. It 
was not possible to determine how many of these patients had a previous 
spontaneous preterm birth. In this trial,120 a total of 104 women with no signs of 
infection or inflammation of the lower genital tract and a cervical length <25 mm 
between 16 and 26 weeks of gestation were randomly allocated to one of the three 
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groups. Overall, there were no significant differences between the cerclage and no 
cerclage groups in the risk of preterm birth and adverse perinatal outcomes. It is 
very unlikely that the significant beneficial effects of cerclage on the risk of preterm 
birth and perinatal morbidity and mortality become non-significant after the 
inclusion of data from this study in the meta-analyses. Third, 20% of women in the 
control group of trials evaluating cerclage received 17-OHPC compared with none 
in the control group of trials evaluating vaginal progesterone. This difference could 
potentially mean that the control groups, which were used as the common 
comparator, are not similar. Notwithstanding, the sensitivity analysis performed by 
excluding these patients showed no significant differences in the results obtained 
with overall meta-analyses. In addition, there is no evidence that 17-OHPC can 
decrease the risk of preterm birth in women with a singleton gestation and a short 
cervix.124-126 Finally, maternal side effects associated with cerclage use such as 
vaginal discharge, infection, and bleeding were not reported in the IPD meta-
analysis that evaluated this intervention,82 which precluded comparisons with those 
reported in trials that evaluated vaginal progesterone.     
Maternal adverse events and long-term childhood outcomes related to 
interventions 
At the time of translating the results from this updated indirect comparison meta-
analysis into practice, some considerations are necessary. Given the apparent 
similar efficacy between vaginal progesterone and cerclage, differences in 
maternal adverse events and long-term childhood outcomes are key variables that 
clinicians and patients with a singleton gestation and previous spontaneous 
preterm birth should consider when selecting an optimal treatment for a 
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sonographic short cervix in the midtrimester. Cerclage placement has been 
associated with complications such as rupture of membranes, chorioamnionitis, 
bleeding, and cervical lacerations.86 Additionally, cerclage is a surgical intervention 
which is usually performed under general or spinal anesthesia, and as such is at 
risk of surgical complications. The trial by Owen et al,116 which contributed 60% of 
patients to the IPD meta-analysis that evaluated cerclage,82 reported that surgical 
and anesthetic complications that were associated with cerclage placement were 
uncommon. The Cochrane review that assessed the use of cerclage for preventing 
preterm birth in women with singleton gestations at high risk for this entity reported 
that cerclage, compared with no treatment, significantly increased the rates of 
maternal fever (6% versus 2%; RR, 2.39, 95% CI, 1.35-4.23) and cesarean 
delivery (18% versus 15%; RR, 1.19; 95% CI, 1.01-1.40).123 Moreover, cerclage 
was associated with a non-significant increase in the risk of maternal side effects 
(vaginal discharge, bleeding, or pyrexia not requiring antibiotics; RR, 2.25; 95% CI, 
0.89-5.69).  
Several systematic reviews and meta-analyses that evaluated the efficacy 
and safety of vaginal progesterone for preventing preterm birth in singleton and 
twin gestations, have reported that the rates of maternal adverse events, 
discontinuation of treatment because of adverse effects, and congenital anomalies 
did not differ significantly between the vaginal progesterone and placebo/no 
treatment groups.70,81,127-129 With regard to long-term childhood outcomes, current 
evidence suggests that in-utero exposure to vaginal progesterone, administered in 
singleton or twin gestations for the prevention of preterm birth, has no any  harmful 
effect on neurodevelopmental outcomes at least until 8 years of age.91,130-134 No 
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studies have reported on long-term neurodevelopmental outcomes in children 
whose mothers received a cerclage.134  
Cost-effectiveness of interventions     
Evidence from several studies indicates that the combination of universal 
transvaginal cervical length screening and vaginal progesterone administration to 
women with a short cervix is a cost-effective intervention that reduces preterm birth 
and perinatal morbidity and mortality.135-144 Moreover, emerging evidence from 
recent studies conducted in hospitals located in the United States144-146 and one 
Australian state147 suggests that the implementation of universal cervical length 
screening and vaginal progesterone administration to patients with a sonographic 
short cervix is associated with a significant reduction in the rates of preterm birth. 
Several of these studies included women with a previous spontaneous preterm 
birth.135,139,140,142,143,146-148  
We identified three studies, all published in abstract form only, which have 
evaluated the cost-effectiveness of cerclage in women with a short cervix.149-151 In 
2011, Miller and Grobman149 compared 17-OHPC alone versus ultrasonographic 
cervical length screening with cerclage placement for women with a cervical length 
<15 mm. This strategy was more costly and less effective than the 17-OHPC only 
strategy. The authors concluded that “cervical length screening for possible 
cerclage placement is not, under most circumstances, a cost-effective strategy to 
prevent recurrent preterm birth”. In 2015, Eke et al150 evaluated the cost-
effectiveness of vaginal progesterone compared to cerclage in patients with a 
sonographically short cervix. Treatment with vaginal progesterone, as compared to 
cerclage, was associated with lower incidence of preterm birth and resulted in 
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better efficacy. In 80% of simulations, vaginal progesterone was cost saving in 
comparison with cerclage. The authors of this study concluded that vaginal 
progesterone was the most cost effective strategy in treating women with a short 
cervix. Finally, Gray et al151 performed a decision and cost analysis about serial 
cervical length screening in women with a singleton gestation and a previous 
spontaneous preterm birth. Patients with a cervical length ≤25 mm would be 
treated with vaginal progesterone, cerclage or a pessary. This study reported that 
cervical length screening and treatment with cerclage was the most costly strategy 
but was the most effective in reducing preterm births.   
Clinical practice guidelines  
Currently, the National Institute for Health and Care Excellence,74 recommends 
offering either vaginal progesterone or cerclage to women with a singleton 
gestation, previous spontaneous preterm birth and a midtrimester cervical length 
<25 mm. The International Federation of Gynecology and Obstetrics recommends 
vaginal progesterone in women with a singleton gestation and a cervical length ≤25 
mm regardless of obstetrical history.73 The  Society  for  Maternal-Fetal  
Medicine,84,87,152 and the  American  Congress of Obstetricians and 
Gynecologists85,86 recommend considering the placement of a cerclage in patients 
with a singleton gestation, previous spontaneous preterm birth, and a cervical 
length <25 mm before 24 weeks of gestation. This recommendation was based 
mainly on the findings of the IPD meta-analysis that assessed the use of cerclage 
in women with these characteristics.82 In a recently published viewpoint article,88 Dr 
Vincenzo Berghella, the lead author of the IPD meta-analysis that evaluated the 
efficacy of cerclage in women with a singleton gestation, previous spontaneous 
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preterm birth, and a cervical length <25 mm, wrote about his study that “after 17 
years of collaborative research, a meta-analysis of randomized controlled trials on 
cerclage for singleton gestations with a prior spontaneous preterm birth and with a 
short transvaginal ultrasound cervical length <25mm before 24 weeks led to new 
clinical recommendations worldwide. This is an example of the power of meta-
analyses, of why I like them, and why I think you should like them too. Many 
societies rank meta-analyses of randomized controlled trials as the best level of 
evidence, even above that of a single randomized controlled trial”. We strongly 
agree with Dr Berghella’s statement and believe that the same applies to both our 
updated IPD meta-analysis showing that vaginal progesterone also decreases 
preterm birth and improves perinatal outcomes in patients with a singleton 
gestation, previous spontaneous preterm birth, and a cervical length <25 mm, and 
our updated adjusted indirect comparison meta-analysis demonstrating that vaginal 
progesterone and cerclage are equally efficacious in preventing preterm birth in 
these patients. Therefore, professional/scientific organizations need to revise their 
recommendations to clinicians, based on the available evidence and recommend 
that vaginal progesterone be offered as an alternative to cerclage in patients with a 
singleton gestation, previous spontaneous preterm birth, and a cervical length <25 
mm before 24 weeks of gestation.            
Implications for practice 
In summary, either vaginal progesterone or cerclage can be used for preventing 
preterm birth and improving perinatal outcomes in patients with a singleton 
gestation, previous spontaneous preterm birth, and a midtrimester sonographic 
short cervix. Thus, other criteria besides efficacy may play a role in therapeutic 
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decision-making, including maternal adverse events and cost-effectiveness of 
interventions, and the patient and physician’s preferences. 
Implications for research 
Adequately powered randomized controlled trials directly comparing vaginal 
progesterone and cerclage would provide the best estimates of efficacy, but such 
trials would require a large sample size given the relatively similar efficacy of these 
interventions. These studies should determine the cost-effectiveness of 
interventions and assess the long-term effects of these strategies on childhood 
outcomes. In the interim, we believe that our indirect comparison meta-analysis 
represents the best available evidence for consideration in guiding clinical practice. 
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TABLE 1. Characteristics of studies included in the indirect comparison meta-analysis 
 
 
 
 
 
Study, year 
 
 
 
Trial enrolment 
 
 
Participants randomly assigned in 
original trial  
 
Participants 
eligible for 
ICMA 
 
 
 
Treatment groups 
 
 
 
Primary outcome 
 
Vaginal progesterone compared with placebo 
 
 
Fonseca,108 
2007 
 
8 centers in United 
Kingdom, Chile, Brazil, 
and Greece 
 
250 with a singleton or twin gestation and a 
cervical length ≤15 mm  
 
 
38 
 
Vaginal progesterone 200 mg/day or 
placebo from 24-33 6/7 weeks of 
gestation  
 
Spontaneous 
preterm birth <34 
weeks 
 
O'Brien,109 
2007 
 
53 centers in United 
States, South Africa, 
India, Czech Republic, 
Chile, and El Salvador 
 
659 with a singleton gestation and previous 
spontaneous preterm birth  
 
 
 
22 
 
Vaginal progesterone 90 mg/day or 
placebo from 18-22 to 37 0/7 weeks of 
gestation, rupture of membranes or 
preterm delivery, whichever occurred first 
 
Preterm birth ≤32 
weeks 
 
Cetingoz,110 
2011 
 
Single center in Turkey 
 
160 with twin gestation, or singleton 
gestation with previous spontaneous 
preterm birth, or uterine malformation  
 
6 
 
Vaginal progesterone suppository 100 
mg/day or placebo from 24-34 weeks of 
gestation  
 
Preterm birth <37 
weeks 
      
 
Hassan,111 
2011 
 
44 centers in United 
States, Belarus, Chile, 
Czech Republic, India, 
Israel, Italy, Russia, South 
Africa, and Ukraine  
 
465 with a singleton gestation and a 
cervical length between 10-20 mm 
 
 
 
92 
 
Vaginal progesterone 90 mg/day or 
placebo from 20-23 6/7 to 36 6/7 weeks of 
gestation, rupture of membranes or 
preterm delivery, whichever occurred first   
 
Preterm birth <33 
weeks 
 
Norman,91 
2016 
 
66 centers in United 
Kingdom and Sweden 
 
1228 with a singleton gestation and 
previous spontaneous preterm birth, or 
cervical length ≤25 mm, or a positive fetal 
fibronectin test combined with other clinical 
risk factors for preterm birth  
 
 
107 
 
Vaginal progesterone 200 mg/day or 
placebo from 22-24 to 34 weeks of 
gestation or preterm delivery, whichever 
occurred first   
 
 
Preterm birth <34 
weeks or fetal death; 
composite of death, 
bronchopulmonary 
dysplasia or brain 
injury; and cognitive 
composite score at 2 
years of age 
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 2 
 
 
 
Cerclage compared with no cerclage 
 
 
Rust,112 
2001 
 
Single center in United 
States 
 
113 with a singleton or multiple gestation 
and transvaginal sonographic dilation of the 
internal os with either membrane prolapse 
into the endocervical canal at least 25% of 
the total cervical length but not beyond the 
external os or a cervical length <25 mm 
 
102 
 
McDonald procedure with a single stitch 
of permanent monofilament or no 
cerclage 
 
Gestational age at 
delivery and neonatal 
morbidity 
 
Althuisius,113 
2001 
 
Single center in The 
Netherlands 
 
36 with a singleton gestation, risk factors 
and/or symptoms of cervical incompetence, 
and a cervical length <25 mm  
 
 
26 
 
McDonald procedure with braided 
polyester thread or no cerclage 
 
Preterm birth <34 
weeks, and neonatal 
morbidity and 
mortality 
 
To,114 2004 
 
12 centers in United 
Kingdom, Brazil, South 
Africa, Slovenia, Greece, 
and Chile 
 
253 with a singleton gestation and a 
cervical length ≤15 mm 
 
44 
 
Shirodkar suture with mersilene tape or 
no cerclage  
 
Preterm birth <33 
weeks 
 
Berghella,115 
2004 
 
2 centers in United States 
 
61 with a singleton or twin gestation and a 
cervical length <25 mm or funneling >25% 
 
31 
 
McDonald procedure with  mersilene tape 
or no cerclage 
 
Preterm birth <35 
weeks 
 
Owen,116 
2009 
 
15 centers in United 
States 
 
302 with a singleton gestation, previous 
spontaneous preterm birth, and cervical 
length <25 mm  
 
301 
 
McDonald procedure with nonabsorbable 
suture (braided tape) or no cerclage 
 
Preterm birth <35 
weeks 
 
ICMA, indirect comparison meta-analysis 
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TABLE 2. Direct comparisons: vaginal progesterone versus placebo and cerclage versus no cerclage   
 
 
 
 
 
 
Outcome 
 
Vaginal progesterone versus placebo 
 
 
Cerclage versus no cerclage
No. of 
trials 
Vaginal 
progesterone 
 
Placebo 
 
RR (95% CI) 
Heterogeneity 
І
2 (%) 
NNT  
(95% CI) 
No. of 
trials 
 
Cerclage 
 
No cerclage 
 
RR (95% CI)
 
Primary outcomes 
          
    
Preterm birth <35 weeks 
 
5 
 
44/139 (32%) 
 
58/126 (46%) 
 
0.68 (0.50-0.93) 
 
0 
 
7 (4-31) 
 
5 
 
71/250 (28%) 
 
105/254 (41%) 
 
0.70 (0.55
 
Perinatal mortality 
 
5 
 
7/139 (5%) 
 
10/126 (8%) 
 
0.63 (0.26-1.56) 
 
0 
 
--- 
 
5 
 
22/250 (9%) 
 
35/254 (14%) 
 
0.65 (0.40
 
Secondary outcomes 
          
 
Preterm birth <37 weeks 
 
5 
 
67/139 (48%) 
 
74/126 (59%) 
 
0.82 (0.65-1.02) 
 
0 
 
--- 
 
5 
 
105/250 (42%) 
 
154/254 (61%) 
 
0.70 (0.58
 
Preterm birth <32 weeks 
 
5 
 
27/139 (19%) 
 
40/126 (32%) 
 
0.60 (0.39-0.92) 
 
0 
 
8 (5-39) 
 
5 
 
48/250 (19%) 
 
75/254 (30%) 
 
0.66 (0.48
    
Preterm birth <28 weeks 
 
5 
 
18/139 (13%) 
 
23/126 (18%) 
 
0.68 (0.39-1.19) 
 
0 
 
--- 
 
5 
 
32/250 (13%) 
 
51/254 (20%) 
 
0.64 (0.43
 
Respiratory distress  
syndrome 
 
4 
 
3/75 (4%) 
 
12/83 (14%) 
 
0.38 (0.13-1.07) 
 
7 
 
--- 
 
4 
 
13/207 (6%) 
 
21/196 (11%) 
 
0.61 (0.32
Grade III/IV  
intraventricular     
hemorrhage 
 
5 
 
1/137 (1%) 
 
3/126 (2%) 
 
0.50 (0.08-2.96) 
 
8 
 
--- 
 
4 
 
0/207 (0%) 
 
4/196 (2%) 
 
0.28 (0.05
 
Necrotizing enterocolitis 
 
5 
 
3/137 (2%) 
 
3/126 (2%) 
 
0.84 (0.19-3.77) 
 
0 
 
--- 
 
4 
 
1/207 (1%) 
 
2/196 (1%) 
 
0.62 (0.08
 
Neonatal sepsis 
 
5 
 
5/137 (4%) 
 
13/126 (10%) 
 
0.38 (0.15-0.96) 
 
0 
 
16 (11-242) 
 
4 
 
8/207 (4%) 
 
17/196 (9%) 
 
0.47 (0.21
 
Bronchopulmonary    
dysplasia 
 
 
3 
 
5/113 (4%) 
 
6/90 (7%) 
 
0.61 (0.20-1.83) 
 
0 
 
--- 
 
1 
 
7/135 (5%) 
 
6/127 (5%) 
 
1.10 (0.38
 
Composite neonatal    
morbidityc 
 
4 
 
3/75 (4%) 
 
16/83 (19%) 
 
0.29 (0.11-0.81) 
 
0 
 
7 (6-27) 
 
4 
 
17/207 (8%) 
 
28/196 (14%) 
 
0.60 (0.3
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Composite perinatal    
morbidity/mortalityd  
 
4 
 
7/75 (9%) 
 
20/83 (24%) 
 
0.43 (0.20-0.94) 
 
0 
 
7 (5-69) 
 
5 
 
39/250 (16%) 
 
63/254 (25%) 
 
0.64 (0.45
 
Admission to NICU 
 
5 
 
26/138 (19%) 
 
51/126 (40%) 
 
0.46 (0.30-0.70) 
 
0 
 
5 (4-8) 
 
4 
 
57/207 (28%) 
 
67/196 (34%) 
 
0.63 (0.34
 
Birthweight <2500 g 
 
5 
 
56/139 (40%) 
 
65/126 (52%) 
 
0.78 (0.59-1.02) 
 
0 
 
--- 
 
5 
 
86/250 (34%) 
 
117/249 (47%) 
 
0.65 (0.42
 
Birthweight <1500 g 
 
 
5 
 
24/139 (17%) 
 
31/126 (25%) 
 
0.67 (0.42-1.08) 
 
0 
 
--- 
 
5 
 
42/250 (17%) 
 
66/249 (27%) 
 
0.64 (0.45
 
CI, confidence interval; NICU, neonatal intensive care unit; NNT, number needed to treat; RR, relative risk 
a
 For the Mantel-Haenszel Q statistics (test of heterogeneity); b For the test of association; c Occurrence of any of the following events: respiratory 
distress syndrome, grade III/IV intraventricular hemorrhage, necrotizing enterocolitis, neonatal sepsis, or bronchopulmonary dysplasia; d 
Occurrence of any of the following events: respiratory distress syndrome, grade III/IV intraventricular hemorrhage, necrotizing enterocolitis, 
neonatal sepsis, bronchopulmonary dysplasia, or perinatal death  
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TABLE 3. Indirect comparison: vaginal progesterone versus cerclage 
 
 
 
 
 
 
Outcome 
Vaginal progesterone  
versus cerclage 
 
 
RR (95% CI)a 
 
P valueb 
 
 
Primary outcomes 
  
    
Preterm birth <35 weeks 
 
0.97 (0.66-1.44)  
 
0.93 
 
Perinatal mortality 
 
0.97 (0.35-2.69)  
 
0.96 
 
Secondary outcomes 
  
 
Preterm birth <37 weeks 
 
1.17 (0.88-1.56)  
 
0.61 
 
Preterm birth <32 weeks 
 
0.91 (0.53-1.55)  
 
0.79 
    
Preterm birth <28 weeks 
 
1.06 (0.53-2.11)  
 
0.89 
 
Respiratory distress syndrome 
 
0.62 (0.18-2.16)  
 
0.84 
 
Grade III/IV  intraventricular hemorrhage 
 
1.79 (0.15-22.00)  
 
0.76 
 
Necrotizing enterocolitis 
 
1.36 (0.11-16.89)  
 
0.84 
 
Neonatal sepsis 
 
0.81 (0.24-2.76)  
 
0.76 
 
Bronchopulmonary dysplasia 
 
0.56 (0.12-2.57)  
 
0.49 
 
Composite neonatal morbidityc 
 
0.48 (0.15-1.53)  
 
0.75 
    
Composite perinatal morbidity/mortalityd  
 
0.67 (0.29-1.57)  
 
0.86 
 
Admission to NICU 
 
0.73 (0.34-1.55)  
 
0.38 
 
Birthweight <2500 g 
 
1.20 (0.72-2.00)  
 
0.56 
 
Birthweight <1500 g 
 
 
1.05 (0.58-1.88)  
 
0.90 
 
CI, confidence interval; NICU, neonatal intensive care unit; RR, relative risk 
a RR <1 favors vaginal progesterone and RR >1 favors cerclage; b For the test of association; c 
Occurrence of any of the following events: respiratory distress syndrome, grade III/IV intraventricular 
hemorrhage, necrotizing enterocolitis, neonatal sepsis, or bronchopulmonary dysplasia; d Occurrence of 
any of the following events: respiratory distress syndrome, grade III/IV intraventricular hemorrhage, 
necrotizing enterocolitis, neonatal sepsis, bronchopulmonary dysplasia, or perinatal death 
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TABLE 4. Subgroup and sensitivity analyses  
 
 
 
 
Direct comparisons 
 
 
Indirect comparison 
 
 
Vaginal progesterone versus placebo 
 
 
Cerclage versus no cerclage 
Vaginal progesterone 
versus cerclage 
 
Outcome 
Vaginal 
progesterone 
 
 
Placebo 
 
RR (95% CI) 
 
Cerclage 
 
No cerclage 
 
 
RR (95% CI) 
 
RR (95% CI) 
P  
valuea 
 
Women with a cervical length <16 mm 
 
   Preterm birth <35 weeks 
 
22/58 (38%) 
 
31/55 (56%) 
 
0.64 (0.42-0.98) 
 
28/80 (35%) 
 
43/74 (58%) 
 
0.59 (0.42-0.83)  
 
1.09 (0.63-1.87) 
 
0.87 
 
   Preterm birth <32 weeks 
 
18/58 (31%) 
 
23/55 (42%) 
 
0.69 (0.42-1.14) 
 
18/80 (23%) 
 
33/74 (45%) 
 
0.50 (0.32-0.78)  
 
1.38 (0.71-2.69)  
 
0.54 
 
   Perinatal mortality    
 
2/58 (3%) 
 
5/55 (9%) 
 
0.39 (0.10-1.51) 
 
11/80 (14%) 
 
16/74 (22%) 
 
0.59 (0.31-1.14) 
 
0.66 (0.15-2.98)  
 
0.67 
 
Women without co-interventions for a short cervix 
 
   Preterm birth <35 weeks 
 
35/117 (30%) 
 
53/118 (45%) 
 
0.66 (0.47-0.94) 
 
57/203 (28%) 
 
85/201 (42%) 
 
0.67 (0.51-0.88)  
 
0.99 (0.63-1.53)  
 
0.97 
 
   Preterm birth <32 weeks 
 
21/117 (18%) 
 
37/118 (31%) 
 
0.57 (0.36-0.91) 
 
40/203 (20%) 
 
64/201 (32%) 
 
0.63 (0.45-0.88)  
 
0.91 (0.51-1.60)  
 
0.80 
 
   Perinatal mortality 
    
 
6/117 (5%) 
 
10/118 (8%) 
 
0.58 (0.22-1.51) 
 
19/203 (9%) 
 
33/201 (16%) 
 
0.58 (0.35-0.98) 
 
1.00 (0.34-2.98)  
 
1.00 
 
CI, confidence interval; RR, relative risk 
a For the test of association   
 
 
 
